N/A N=34 Food Preference Following Bariatric Surgery
Obesity
Primary: Total Food Intake (Lunch Buffet) at 24 Months — 2540.1; 721 kJ
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 Safety and Efficacy of Long Limb Roux-en Y Reconstruction
Diabetes Mellitus Type 2 in Nonobese · Gastric Cancer
Primary: Morbidity — 4 participants
N/A N=72 Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity
Morbid Obesity · Metabolic Syndrome X · Diabetes Mellitus
Primary: Excess Weight Loss From Baseline — 67.8; 64.2 percentage of EWL
N/A N=150 Gastric Procedures for Obesity
Morbid Obesity
Primary: Change in Body Weight — -21.4; -36.6; -7.0 kg
N/A N=100 GAstric Bypass to Treat obEse Patients With steAdy hYpertension
Systemic Hypertension · Obesity
Primary: Number of Participants With a Reduction in the Number of Anti-hypertensive Drugs Used and Maintaining Blood Pressure Below 140x90mmHg — 41; 6 Participants
N/A N=22 Diabetes and Gastric By- Pass
Type 2 Diabetes
Primary: Response in Glucose AUC at Baseline vs. Following Gastric Bypass Surgery — 61647.0; 59476.1 mg/dL*min
N/A N=30 Low-calorie Diet and Body Composition Prior to Roux-en-Y Gastric Bypass
Morbid Obesity · Liver Fat
Primary: Change in Intra-hepatocellular Lipid Content (IHCL) Following the Pre-operative Diet — 40.0; 67.4; 0.1 percentage of change in IHCL
N/A N=62 Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
Hypoglycemia · Obesity
Primary: Mean Serum Glucose Levels — 123.1; 157.5; 103.2; 138 mg/dl
N/A N=355 Evaluation of Endostapled Anastomoses for Laparoscopic Gastric Bypass (EEA-LGB)
Morbid Obesity
Primary: Number of Participants With Postoperative Gastrointestinal Hemorrhage — 13; 39 participants
Phase 3 N=20 Effects of Gastric Bypass on Blood Levels of Duloxetine
Bariatric Surgery
Primary: Cmax — 51.04; 61.41 ng/ml
N/A N=55 Effects of Gastric Bypass Surgery and Calcium Metabolism and the Skeleton
Obesity, Morbid · Gastric Bypass
Primary: Change in Intestinal Calcium Absorption — -25.8 % of ingested calcium that is absorbed
N/A N=25 Use of Radiofrequency Ablation for RGB Salvage
Obesity
Primary: Excess Body Weight Loss After RFA Treatment — 28.36 percentage of EBWL
N/A N=30 Ileal Interposition With Sleeve Gastrectomy for Control of Diabetes
Diabetes
Primary: Percentage of Participants Having Remission of Type 2 Diabetes — 76.66 Percentage of Participants
N/A N=197 Laparoscopic Gastric Bypass vs LAP-BAND for Treatment of Morbid Obesity
Morbid Obesity
Primary: Excess Weight Loss From Pre-operation to 5 Years Post-operation — 68.4; 45.4 percent change
Phase 2 N=12 The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Glucose — 6.1; 7.23; 6.48; 5.89 mmol/l
N/A N=53 Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass
Gastroesophageal Reflux Disease · Morbid Obesity
Primary: Number of Participants Presenting Reflux Symptoms — 31; 8; 5 participants — p=<0.001
Phase 2 N=31 Trial of Leptin Administration After Roux-en-Y Gastric Bypass
Overweight
Primary: Weight Change (in kg.) After Each Intervention — -0.39; 0.02 kg weight change
N/A N=24 Endoscopic Surgery for Bariatric Revision After Weight Loss Failure
Morbid Obesity · Weight Loss
Primary: Mean Weight Loss — 13.3 Pounds
N/A N=20 Endoscopic Suturing for Primary Obesity Treatment
Obesity · Body Weight · Overweight
Primary: Number of Participants With Adverse Events — 5; 2; 0; 13 Participants
N/A N=41 The Effects of Glycemic Optimization Before Gastric Bypass Surgery
Type 2 Diabetes
Primary: Composite of Fasting Glucose, Glycosylated Haemoglobin c and Rates of Type 2 Diabetes Mellitus Remission. — 6; 6 Participants
Phase 4 N=11 The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery
Hypoglycemia
Primary: Difference Score: Percent of Time Spent in Hypoglycemic State — 1.2 Difference score, trt-control (percent) — p=0.99
N/A N=15 Assessment of Gastric Volume Reduction in Surgical Weight Loss Candidates
Obesity
Primary: Successful Gastric Plication Using Reduction Gastroplasty — 9; 6 participants
N/A N=293 Clinical and Economic Outcomes in Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass Surgery
Morbid Obesity
Primary: Quality of Life (QOL) in First Postoperative Year According to EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) — 3; 3 Score*months
N/A N=25,038 Risk Factors Predicting Serious Complications With Laparoscopic Gastric Bypass Surgery
Postoperative Complications
Primary: Serious Complications — 630 Participants
Phase 3 N=46 Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
Obesity
Primary: Weight — 127; 130; 126; 75 kilograms
Phase 4 N=36 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
Bariatric Surgery Candidate · Bone Loss
Primary: Percentage Change in Total Hip Bone Mineral Density — 0.60; -6.44 percentage of change
Phase 4 N=61 Preoperative Pain Control in Gastric Bypass Surgery Patients
Post-operative Pain
Primary: Post-operative Pain Medication Requirements — 13.76; 17.32; 40.89; 46.63 MME — p=0.10
N/A N=39 Sonographic Evaluation of Visceral Fat After Bariatric Surgery
Morbid Obesity
Primary: Decrease in the Visceral Fat Layer Measured by Ultrasound a Day Before and a Year After Surgery. — 3.6; 7.1; 5.6 visceral fat reduction in centimeters
Phase 4 N=132 Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery
Obesity
Primary: Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test — 76; 17 percentage of participants
N/A N=8 The Effect of Macronutrients on Satiety and Gut Hormone Responses
Eating Behavior
Primary: The Effect of Proteins on the Secretion of Gut Hormones From Different Parts of the Gastrointestinal Tract — 1310; 1073; 1118; 1188 pg*min/mL